Korean J Pediatr Hematol Oncol.  2004 Oct;11(2):276-279.

A Case of Successful Treatment of Childhood Intractable Gastrointestinal Hemorrhage with Low Dose Recombinant Activated Factor VII (NovoSeven (R))

Affiliations
  • 1Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea. kslee@knu.ac.kr

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven (R)) was initially developed for the treatment of bleeding in patients with hemophilia having antibodies against factor VIII or IX, and factor VII deficiency. Although the precise mode of action is still elusive and there are just several hypotheses, recently case reports have suggested a role of rFVIIa in the management of intractable or life-threatening bleeding in some non-hemophilic patients who do not respond to conventional treatments. We report the successful use of rFVIIa in a pediatric patient with intractable gastrointestinal bleeding.

Keyword

Intractable gastrointestinal bleeding; Recombinant activated factor VII (rFVIIa); Childhood

MeSH Terms

Antibodies
Factor VII Deficiency
Factor VIIa*
Factor VIII
Gastrointestinal Hemorrhage*
Hemophilia A
Hemorrhage
Humans
Antibodies
Factor VIII
Factor VIIa
Full Text Links
  • KJPHO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error